New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
08:51 EDTJAZZJazz Pharmaceuticals price target raised to $70 from $63 at WallachBeth
WallachBeth raised its price target for Jazz Pharmaceuticals following the company's better than expected Q4 results and reiterates a Buy rating on the stock. The firm believes Jazz's outlook leaves room for upside.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:51 EDTJAZZOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 8, 2014
08:17 EDTJAZZJazz Pharmaceuticals executing on all cylinders, says Stifel
Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.
07:21 EDTJAZZJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use